44.25 USD
+0.04 (+0.09%)
At close: Feb 11, 2026
44.25 USD
0 (0%)
After Hours: 2/11/2026, 8:00:01 PM
Overall RPRX gets a fundamental rating of 6 out of 10. We evaluated RPRX against 191 industry peers in the Pharmaceuticals industry. RPRX has an excellent profitability rating, but there are some minor concerns on its financial health. RPRX is valued quite cheap, while showing a decent growth score. This is a good combination!
1. Profitability
1.1 Basic Checks
- In the past year RPRX was profitable.
- In the past year RPRX had a positive cash flow from operations.
- RPRX had positive earnings in each of the past 5 years.
- RPRX had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- RPRX has a better Return On Assets (3.95%) than 84.82% of its industry peers.
- RPRX has a better Return On Equity (11.93%) than 85.86% of its industry peers.
- Looking at the Return On Invested Capital, with a value of 6.43%, RPRX belongs to the top of the industry, outperforming 84.29% of the companies in the same industry.
- Measured over the past 3 years, the Average Return On Invested Capital for RPRX is significantly below the industry average of 12.66%.
- The 3 year average ROIC (5.98%) for RPRX is below the current ROIC(6.43%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.95% | ||
| ROE | 11.93% | ||
| ROIC | 6.43% |
ROA(3y)3.97%
ROA(5y)3.7%
ROE(3y)10.17%
ROE(5y)10.3%
ROIC(3y)5.98%
ROIC(5y)6.56%
1.3 Margins
- RPRX's Profit Margin of 32.55% is amongst the best of the industry. RPRX outperforms 95.29% of its industry peers.
- RPRX's Profit Margin has declined in the last couple of years.
- With an excellent Operating Margin value of 65.22%, RPRX belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
- RPRX's Operating Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 65.22% | ||
| PM (TTM) | 32.55% | ||
| GM | N/A |
OM growth 3Y-2.96%
OM growth 5Y-16.96%
PM growth 3Y11.92%
PM growth 5Y-21.76%
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so RPRX is destroying value.
- The number of shares outstanding for RPRX has been reduced compared to 1 year ago.
- Compared to 5 years ago, RPRX has more shares outstanding
- Compared to 1 year ago, RPRX has a worse debt to assets ratio.
2.2 Solvency
- An Altman-Z score of 1.82 indicates that RPRX is not a great score, but indicates only limited risk for bankruptcy at the moment.
- RPRX has a Altman-Z score (1.82) which is comparable to the rest of the industry.
- The Debt to FCF ratio of RPRX is 9.47, which is on the high side as it means it would take RPRX, 9.47 years of fcf income to pay off all of its debts.
- With a decent Debt to FCF ratio value of 9.47, RPRX is doing good in the industry, outperforming 79.58% of the companies in the same industry.
- RPRX has a Debt/Equity ratio of 1.34. This is a high value indicating a heavy dependency on external financing.
- RPRX's Debt to Equity ratio of 1.34 is on the low side compared to the rest of the industry. RPRX is outperformed by 75.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.34 | ||
| Debt/FCF | 9.47 | ||
| Altman-Z | 1.82 |
ROIC/WACC0.74
WACC8.67%
2.3 Liquidity
- A Current Ratio of 3.48 indicates that RPRX has no problem at all paying its short term obligations.
- RPRX's Current ratio of 3.48 is in line compared to the rest of the industry. RPRX outperforms 54.97% of its industry peers.
- RPRX has a Quick Ratio of 3.48. This indicates that RPRX is financially healthy and has no problem in meeting its short term obligations.
- RPRX has a Quick ratio (3.48) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.48 | ||
| Quick Ratio | 3.48 |
3. Growth
3.1 Past
- The Earnings Per Share has been growing slightly by 0.24% over the past year.
- RPRX shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -18.23% yearly.
- RPRX shows a small growth in Revenue. In the last year, the Revenue has grown by 3.70%.
- The Revenue has been growing slightly by 4.52% on average over the past years.
EPS 1Y (TTM)0.24%
EPS 3Y22.51%
EPS 5Y-18.23%
EPS Q2Q%15.84%
Revenue 1Y (TTM)3.7%
Revenue growth 3Y-0.38%
Revenue growth 5Y4.52%
Sales Q2Q%44.07%
3.2 Future
- RPRX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.53% yearly.
- Based on estimates for the next years, RPRX will show a quite strong growth in Revenue. The Revenue will grow by 10.65% on average per year.
EPS Next Y13.78%
EPS Next 2Y12.48%
EPS Next 3Y12.99%
EPS Next 5Y10.53%
Revenue Next Year17.9%
Revenue Next 2Y9.71%
Revenue Next 3Y8.83%
Revenue Next 5Y10.65%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 10.77, which indicates a very decent valuation of RPRX.
- Based on the Price/Earnings ratio, RPRX is valued cheaper than 90.58% of the companies in the same industry.
- RPRX is valuated cheaply when we compare the Price/Earnings ratio to 28.23, which is the current average of the S&P500 Index.
- A Price/Forward Earnings ratio of 8.53 indicates a reasonable valuation of RPRX.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of RPRX indicates a rather cheap valuation: RPRX is cheaper than 92.15% of the companies listed in the same industry.
- When comparing the Price/Forward Earnings ratio of RPRX to the average of the S&P500 Index (28.01), we can say RPRX is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.77 | ||
| Fwd PE | 8.53 |
4.2 Price Multiples
- Based on the Price/Free Cash Flow ratio, RPRX is valued cheaper than 82.72% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 27.04 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- RPRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The decent profitability rating of RPRX may justify a higher PE ratio.
- RPRX's earnings are expected to grow with 12.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.78
PEG (5Y)N/A
EPS Next 2Y12.48%
EPS Next 3Y12.99%
5. Dividend
5.1 Amount
- RPRX has a Yearly Dividend Yield of 2.13%. Purely for dividend investing, there may be better candidates out there.
- Compared to an average industry Dividend Yield of 0.93, RPRX pays a better dividend. On top of this RPRX pays more dividend than 92.67% of the companies listed in the same industry.
- Compared to an average S&P500 Dividend Yield of 1.79, RPRX has a dividend comparable with the average S&P500 company.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.13% |
5.2 History
- RPRX has been paying a dividend for over 5 years, so it has already some track record.
- RPRX has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)N/A
Div Incr Years4
Div Non Decr Years4
5.3 Sustainability
- RPRX pays out 49.36% of its income as dividend. This is a bit on the high side, but may be sustainable.
DP49.36%
EPS Next 2Y12.48%
EPS Next 3Y12.99%
44.25
+0.04 (+0.09%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-05 2025-11-05/bmo
Earnings (Next)02-11 2026-02-11/bmo
Inst Owners81.5%
Inst Owner Change-1.3%
Ins Owners1.56%
Ins Owner Change-1.45%
Market Cap25.54B
Revenue(TTM)2.35B
Net Income(TTM)764.96M
Analysts84.29
Price Target48.57 (9.76%)
Short Float %7.09%
Short Ratio6.84
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.13% |
Yearly Dividend0.63
Dividend Growth(5Y)N/A
DP49.36%
Div Incr Years4
Div Non Decr Years4
Ex-Date02-20 2026-02-20 (0.235)
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.5%
Min EPS beat(2)3.01%
Max EPS beat(2)9.99%
EPS beat(4)3
Avg EPS beat(4)-10%
Min EPS beat(4)-59.9%
Max EPS beat(4)9.99%
EPS beat(8)5
Avg EPS beat(8)-3.29%
EPS beat(12)9
Avg EPS beat(12)0.42%
EPS beat(16)10
Avg EPS beat(16)-0.98%
Revenue beat(2)2
Avg Revenue beat(2)6.07%
Min Revenue beat(2)4.2%
Max Revenue beat(2)7.95%
Revenue beat(4)3
Avg Revenue beat(4)1.88%
Min Revenue beat(4)-14.22%
Max Revenue beat(4)9.61%
Revenue beat(8)3
Avg Revenue beat(8)-6.2%
Revenue beat(12)3
Avg Revenue beat(12)-10.78%
Revenue beat(16)4
Avg Revenue beat(16)-8.96%
PT rev (1m)4.81%
PT rev (3m)9.5%
EPS NQ rev (1m)2.76%
EPS NQ rev (3m)1.5%
EPS NY rev (1m)-3.01%
EPS NY rev (3m)1.8%
Revenue NQ rev (1m)0.95%
Revenue NQ rev (3m)2.79%
Revenue NY rev (1m)1.44%
Revenue NY rev (3m)2.56%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.77 | ||
| Fwd PE | 8.53 | ||
| P/S | 10.87 | ||
| P/FCF | 27.04 | ||
| P/OCF | 10.62 | ||
| P/B | 3.98 | ||
| P/tB | 4.65 | ||
| EV/EBITDA | N/A |
EPS(TTM)4.11
EY9.29%
EPS(NY)5.19
Fwd EY11.72%
FCF(TTM)1.64
FCFY3.7%
OCF(TTM)4.17
OCFY9.42%
SpS4.07
BVpS11.11
TBVpS9.51
PEG (NY)0.78
PEG (5Y)N/A
Graham Number32.06
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.95% | ||
| ROE | 11.93% | ||
| ROCE | 8.15% | ||
| ROIC | 6.43% | ||
| ROICexc | 7.12% | ||
| ROICexgc | 7.53% | ||
| OM | 65.22% | ||
| PM (TTM) | 32.55% | ||
| GM | N/A | ||
| FCFM | 40.2% |
ROA(3y)3.97%
ROA(5y)3.7%
ROE(3y)10.17%
ROE(5y)10.3%
ROIC(3y)5.98%
ROIC(5y)6.56%
ROICexc(3y)6.7%
ROICexc(5y)7.58%
ROICexgc(3y)6.7%
ROICexgc(5y)7.59%
ROCE(3y)7.57%
ROCE(5y)8.31%
ROICexgc growth 3Y-4.76%
ROICexgc growth 5Y-18.24%
ROICexc growth 3Y-4.74%
ROICexc growth 5Y-18.16%
OM growth 3Y-2.96%
OM growth 5Y-16.96%
PM growth 3Y11.92%
PM growth 5Y-21.76%
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.12
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.34 | ||
| Debt/FCF | 9.47 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 62.15% | ||
| Interest Coverage | -5.67 | ||
| Cash Conversion | N/A | ||
| Profit Quality | 123.5% | ||
| Current Ratio | 3.48 | ||
| Quick Ratio | 3.48 | ||
| Altman-Z | 1.82 |
F-Score5
WACC8.67%
ROIC/WACC0.74
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)92.8%
Cap/Sales(5y)95.39%
Profit Quality(3y)349.23%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0.24%
EPS 3Y22.51%
EPS 5Y-18.23%
EPS Q2Q%15.84%
EPS Next Y13.78%
EPS Next 2Y12.48%
EPS Next 3Y12.99%
EPS Next 5Y10.53%
Revenue 1Y (TTM)3.7%
Revenue growth 3Y-0.38%
Revenue growth 5Y4.52%
Sales Q2Q%44.07%
Revenue Next Year17.9%
Revenue Next 2Y9.71%
Revenue Next 3Y8.83%
Revenue Next 5Y10.65%
EBIT growth 1Y-0.72%
EBIT growth 3Y-3.33%
EBIT growth 5Y-13.2%
EBIT Next Year30.98%
EBIT Next 3Y14.48%
EBIT Next 5Y13.68%
FCF growth 1Y-33.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-13.64%
OCF growth 3Y11.13%
OCF growth 5Y10.68%
ROYALTY PHARMA PLC- CL A / RPRX FAQ
Can you provide the ChartMill fundamental rating for ROYALTY PHARMA PLC- CL A?
ChartMill assigns a fundamental rating of 6 / 10 to RPRX.
What is the valuation status for RPRX stock?
ChartMill assigns a valuation rating of 8 / 10 to ROYALTY PHARMA PLC- CL A (RPRX). This can be considered as Undervalued.
How profitable is ROYALTY PHARMA PLC- CL A (RPRX) stock?
ROYALTY PHARMA PLC- CL A (RPRX) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for RPRX stock?
The Price/Earnings (PE) ratio for ROYALTY PHARMA PLC- CL A (RPRX) is 10.77 and the Price/Book (PB) ratio is 3.98.
Can you provide the dividend sustainability for RPRX stock?
The dividend rating of ROYALTY PHARMA PLC- CL A (RPRX) is 4 / 10 and the dividend payout ratio is 49.36%.